Efficacy and safety of Symbravo® (MoSEICTM meloxicam and rizatriptan) in participants with migraine experiencing an inadequate response to oral CGRP inhibitors: Topline results from the EMERGE trial

Authors
Category Primary study
Conference67th Annual Scientific Meeting
Year 2025
This article has no abstract
Epistemonikos ID: acddd93dd2c8cebc1eccbc7f46005e3cdefb01f9
First added on: Apr 04, 2026